| 1.49 -0.07 (-4.49%) | 03-18 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |   |
|||
| Targets | 6-month : | 2.19 | 1-year : | 2.56 |
| Resists | First : | 1.87 | Second : | 2.19 |
| Pivot price | 1.58 |
|||
| Supports | First : | 1.34 | Second : | 1.01 |
| MAs | MA(5) : | 1.54 |
MA(20) : | 1.45 |
| MA(100) : | 1.28 |
MA(250) : | 1.23 |
|
| MACD | MACD : | 0.1 |
Signal : | 0.1 |
| %K %D | K(14,3) : | 55.5 |
D(3) : | 60.2 |
| RSI | RSI(14): 54.9 |
|||
| 52-week | High : | 1.87 | Low : | 0.81 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ PMVP ] has closed above bottom band by 25.2%. Bollinger Bands are 20.4% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 1.57 - 1.58 | 1.58 - 1.59 |
| Low: | 1.47 - 1.48 | 1.48 - 1.49 |
| Close: | 1.47 - 1.49 | 1.49 - 1.51 |
PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. The company's lead product candidate is PC14586, a small molecule that corrects a p53 protein containing the Y220C mutation and restores wild-type p53 function. It is also developing mutant p53 programs, including Wild-type p53 Induced-Phosphatase, R282W, and R273H, as well as other p53 hotspot mutations. The company was formerly known as PJ Pharmaceuticals, Inc. and changed its name to PMV Pharmaceuticals, Inc. in July 2013. PMV Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Cranbury, New Jersey.
Mon, 16 Mar 2026
PMV Pharmaceuticals, Inc. (NASDAQ:PMVP) Short Interest Update - MarketBeat
Thu, 12 Mar 2026
PMV Pharmaceuticals Advances Rezatapopt Interaction Study, Signaling Steady Progress in TP53-Driven Oncology - TipRanks
Mon, 09 Mar 2026
PMV Pharmaceuticals (PMVP) CFO receives 240,000-share stock option grant - Stock Titan
Mon, 09 Mar 2026
PMV Pharmaceuticals (PMVP) awards CEO 744,960 employee stock options - Stock Titan
Fri, 06 Mar 2026
PMV Pharmaceuticals 10-K: Revenue $0, EPS $(1.48) — FY2025 results - TradingView
Fri, 06 Mar 2026
PMV Pharmaceuticals (NASDAQ: PMVP) highlights 2025 loss, rezatapopt data and cash runway - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 53 (M) |
| Shares Float | 46 (M) |
| Held by Insiders | 3.2 (%) |
| Held by Institutions | 61.3 (%) |
| Shares Short | 1,500 (K) |
| Shares Short P.Month | 1,800 (K) |
| EPS | -1.6 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.96 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -35 % |
| Return on Equity (ttm) | -55.4 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -1.62 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -74 (M) |
| Levered Free Cash Flow | -49 (M) |
| PE Ratio | -0.94 |
| PEG Ratio | 0 |
| Price to Book value | 0.76 |
| Price to Sales | 0 |
| Price to Cash Flow | -1.08 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|